1. Home
  2. EARN vs GBIO Comparison

EARN vs GBIO Comparison

Compare EARN & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EARN
  • GBIO
  • Stock Information
  • Founded
  • EARN 2012
  • GBIO 2016
  • Country
  • EARN United States
  • GBIO United States
  • Employees
  • EARN N/A
  • GBIO N/A
  • Industry
  • EARN Real Estate Investment Trusts
  • GBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • EARN Real Estate
  • GBIO Health Care
  • Exchange
  • EARN Nasdaq
  • GBIO Nasdaq
  • Market Cap
  • EARN 189.7M
  • GBIO 41.2M
  • IPO Year
  • EARN 2013
  • GBIO 2020
  • Fundamental
  • Price
  • EARN $5.21
  • GBIO $6.38
  • Analyst Decision
  • EARN Buy
  • GBIO Buy
  • Analyst Count
  • EARN 2
  • GBIO 4
  • Target Price
  • EARN $5.88
  • GBIO $10.67
  • AVG Volume (30 Days)
  • EARN 350.1K
  • GBIO 44.2K
  • Earning Date
  • EARN 11-11-2025
  • GBIO 11-05-2025
  • Dividend Yield
  • EARN 18.68%
  • GBIO N/A
  • EPS Growth
  • EARN N/A
  • GBIO N/A
  • EPS
  • EARN N/A
  • GBIO N/A
  • Revenue
  • EARN $35,893,000.00
  • GBIO $21,230,000.00
  • Revenue This Year
  • EARN N/A
  • GBIO N/A
  • Revenue Next Year
  • EARN $15.96
  • GBIO N/A
  • P/E Ratio
  • EARN N/A
  • GBIO N/A
  • Revenue Growth
  • EARN 43.30
  • GBIO 61.15
  • 52 Week Low
  • EARN $4.33
  • GBIO $3.00
  • 52 Week High
  • EARN $7.11
  • GBIO $25.70
  • Technical
  • Relative Strength Index (RSI)
  • EARN 39.65
  • GBIO 56.86
  • Support Level
  • EARN $5.10
  • GBIO $6.12
  • Resistance Level
  • EARN $5.20
  • GBIO $6.92
  • Average True Range (ATR)
  • EARN 0.11
  • GBIO 0.32
  • MACD
  • EARN -0.00
  • GBIO -0.03
  • Stochastic Oscillator
  • EARN 37.62
  • GBIO 44.33

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: